India-based pharmaceutical company Granules India has revealed plans to develop a pharmaceutical packaging facility in Virginia, US.

Virginia Governor Glenn Youngkin announced the project, which will require a $12.5m investment.

Located in Prince William County, the facility will be part of Granules India’s Consumer Health division.

The company will lease 79,000ft² of the Parkway 66 property at 7413 Cushing Road in Manassas and develop packaging lines and cleanrooms for packaging and shipping pharmaceutical products.

Granules India founder and managing director Dr Krishna Prasad Chigurupati said: “The addition of a US packaging facility will result in Granules being among the few pharmaceutical companies to be vertically integrated from API to packaging, which will bolster the robustness of Granules’ supply chain while also enabling the company to react even faster to consumers’ growing needs for pharmaceutical products.

“The company chose Virginia because of Prince William County’s responsiveness, which allowed Granules faster access to commercialisation.

“In addition, Prince William offers a dynamic and diverse workforce that is eager to work along with the site’s proximity to several major seaports

Granules India currently has a pharmaceutical research and development and manufacturing facility in Fairfax County, Virginia, which employs 130 colleagues.

The company’s new facility will create 57 jobs and has received a $200,000 grant from the Commonwealth’s Opportunity Fund.

Governor Youngkin said: “Virginia continues to attract pharmaceutical manufacturing, and Granules India’s new packaging operation in Prince William County is an important addition to the pharmaceutical ecosystem in the Commonwealth.

“The company’s decision to expand its footprint in Virginia is a testament to our infrastructure and robust workforce, and we look forward to further development of this partnership.”

Based in Hyderabad, Granules India supplies active pharmaceutical ingredients, pharmaceutical formulation intermediates and finished dosages to brand and generics companies in more than 75 countries.

The company manufactures products such as acetaminophen, ibuprofen and guaifenesin.